Combining the anti-EGFR agent gefitinib with chemotherapy in non-small-cell lung cancer: How do we go from INTACT to impact?

Journal of Clinical Oncology

Volumn 22, Issue 5, 2004, Pages 759-761

  Baselga, Jose ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; GEFITINIB; TRASTUZUMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; QUINAZOLINE DERIVATIVE;

CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; EDITORIAL; HUMAN; IN SITU HYBRIDIZATION; LUNG NON SMALL CELL CANCER; POPULATION RESEARCH; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; CANCER STAGING; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; DRUG ANTAGONISM; FEMALE; LUNG TUMOR; MALE; MORTALITY; NOTE; PATHOLOGY; PHASE 3 CLINICAL TRIAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SURVIVAL; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS, PHASE III; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; NEOPLASM STAGING; PROGNOSIS; QUINAZOLINES; RANDOMIZED CONTROLLED TRIALS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 1542503756     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.12.903     Document Type: Editorial

References (20)

1. Giaccone G, Herbst RS, Manegold C, et al: A phase III clinical trial of Gefitinib, an EGFR inhibitor, in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer (INTACT 1). J Clin Oncol 22:777-784, 2004
2. Herbst RS, Giaccone G, Schiller J, et al: Gefitinib in Combination With Paclitaxel and Carboplatin in Chemotherapy-Naive Patients With Advanced Non-Small-Cell Lung Cancer: Results from a Phase III Clinical Trial (INTACT 2). J Clin Oncol 22:785-794, 2004
3. Fukuoka M, Yano S, Giaccone G. et al: Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 21:2237-2246, 2003
4. Kris MG, Natale RB, Herbst RS, et al: Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: A randomized trial. JAMA 290:2149-2158, 2003
5. Ciardiello F, Caputo R, Bianco R, et al: Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res 6:2053-2063, 2000
6. Sirotnak FM, Zakowsky MF, Miller VA, et al: Efficacy of cytotoxic agents against human tumor xenographs is markedly enhanced by coadministration of ZD1839 (Iressa) an inhibitor of tyrosine kinase. Clin Cancer Res 6:4885-4892, 2000
7. Mendelsohn J, Baselga J: Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 21:2787-2799, 2003
8. Bailey LR, Kris M, Wolf M, et al: Tumor EGFR membrane staining is not clinically relevant for predicting response in patients receiving Gefitinib (Iressa, ZD1839) monotherapy for pretreated advanced non-small-cell lung cancer: IDEAL 1 and 2. Proc Am Assoc Cancer Res 44, 2003 (abstr LB-170)
9. Betensky RA, Louis DN, Cairncross JG: Influence of unrecognized molecular heterogeneity on randomized clinical trials. J Clin Oncol 20:2495-499, 2002
10. Cobleigh MA, Vogel CL, Tripathy D, et al: Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17:2639-2648, 1999
11. Slamon DJ, Leyland-Jones B, Shak S, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792, 2001
12. Vogel CL, Cobleigh MA, Tripathy D, et al: Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20:719-726, 2002
13. Albain KS, Green SJ, Ravdin PM, et al: Adjuvant chemohormonal therapy for primary breast cancer should be sequential instead of concurrent: Initial results from intergroup trial 0100 (SWOG-8814). Proc Am Soc Clin Oncol 21, 2002 (abstr 143)
14. Solit DB, She Y, Moasser M, et al: Pulsatile administration of the EGF receptor inhibitor (Iressa, ZD1839) is significantly more effective that continuosly dosing for sensitizing tumors to Taxol. AACR-NCI-EORTC International Conference Molecular Targets and Cancer Therapeutics, 2003 (abstr 83)
15. Gatzemeier U, Rosell R, Ramlau R, et al: Cetuximab (C225) in combination with cisplatin/vinorelbine alone in the first-line treatment of patients with epidermal growth factor (EGFR) positive advanced non-small-cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 22:642, 2003 (abstr 2582)
16. Cunningham D, Humblet Y, Siena S, et al: Cetuximab (Erbitux) in combination with irinotecan or as single agent in patients with EGFR-expressing, irinotecan-refractory metastatic colorectal cancer. Proc Am Soc Clin Oncol 22:252, 2003 (abstr 1012)
17. van de Vijver MJ, He YD, van't Veer LJ, et al: A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347:1999-2009, 2002
18. Pusztai L, Ayers M, Simmans FW, et al: Emerging science: Prospective validation of gene expression profiling-based prediction of complete pathologic response to neoadjuvant paclitaxel/FAC chemotherapy in breast cancer. Proc Am Soc Clin Oncol 22:1, 2003 (abstr 1)
19. Tabernero J, RoJo F, Jimenez E, et al: A phase I PK and serial tumor and skin pharmacodynamic (PD) study of weekly (q1w), every 2-week (q2w) or every 3-week (q3w) 1-hour (h) infusion EMD72000, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with advanced tumors. Proc Am Soc Clin Oncol 22:172, 2003 (abstr 770)
20. Natale RB, Shak S, Aronson N, et al: Quantitative gene expression in non-small-cell lung cancer from paraffin-embedded tissue specimens: Predicting response to gefitinib, an EGFR kinase inhibitor. Proc Am Soc Clin Oncol 22:170, 2003 (abstr 763)